ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤PROACT 1 eGFR slope topline results remain on track for Q2 2027
- ➤PROACT 1 confirmatory enrollment expected above 500 patients in Q1 2027
- ➤Cash, equivalents and marketable securities totaled $141.9 million at quarter-end
- ➤R&D expenses rose to $40.8 million, up $14.0 million year over year
- ➤Net loss before noncontrolling interest widened to $51.8 million from $35.8 million
Expert Statements
Bruce Culleton, CEO of ProKidney
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027.”
Bruce Culleton, CEO of ProKidney
“The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function.”
Bruce Culleton, CEO of ProKidney
“Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
* On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 * Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by accelerated patient recruitment in mid-2026 * Presented eight abstracts at ASN Kidney Week 2026, with new data further strengthening the mechanistic and clinical evidence supporting rilparencel; subsequently hosted a KOL event recapping key ASN findings and rilparencel’s potential role in advanced CKD and type 2 diabetes * Ended the third quarter with $142 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones.
Get started
Create a free account to read the full story.